Including information about the PLAGL1/PLAGL2 amplification status of each sample, we repeated t-SNE analysis using a select subset of 910 reference tumors of various types—including HGGs, medulloblastomas, and a set of the recently published neuroepithelial tumors with PATZ1 fusions [6]—together with the 33 ET, PLAGL tumors (Fig. 1b). The gene discussed is PLAGL2; the disease is medulloblastoma.